Literature DB >> 27073562

MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6.

Fang Huang1, Yaofeng Jin2, Yafeng Wei1.   

Abstract

MicroRNAs (miRs) are endogenous non-coding RNAs that serve key functions in a wide range of biological processes, including cell growth, development, apoptosis and carcinogenesis. However, the association between miR-187 and B-cell lymphoma 6 (BCL6) has yet to be fully investigated in lymphoma cell apoptosis. The present study hypothesized that a post-translational mechanism may exist for BCL6 expression, which is regulated by miR-187 in lymphoma cells. The present study demonstrated that the expression of miR-187 in diffuse large B-cell lymphoma (DLBCL) cells was significantly decreased, and its expression was negatively correlated with BCL6 expression. It was also observed that miR-187 directly binds to the 3'-untranslated region of BCL6 mRNA and subsequently suppresses the expression of BCL6. Additionally, the induced expression of miR-187 significantly promoted DLBCL cell apoptosis in vitro. The drug sensitivity of human DLBCL SUDHL2 cells was increased following induction of miR-187 overexpression via an miR-187 mimic. In conclusion, the results of the present study suggest that the modulation of miR-187 expression in DLBCL cells may improve the sensitivity of chemotherapy through BCL6 targeting.

Entities:  

Keywords:  B-cell lymphoma 6; apoptosis; diffuse large B-cell lymphoma; miRNA-187; multidrug resistance

Year:  2016        PMID: 27073562      PMCID: PMC4812283          DOI: 10.3892/ol.2016.4313

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.

Authors:  C C Chang; B H Ye; R S Chaganti; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

3.  Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.

Authors:  A Chao; C-Y Lin; Y-S Lee; C-L Tsai; P-C Wei; S Hsueh; T-I Wu; C-N Tsai; C-J Wang; A-S Chao; T-H Wang; C-H Lai
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

4.  miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.

Authors:  Laoighse Mulrane; Stephen F Madden; Donal J Brennan; Gabriela Gremel; Sharon F McGee; Sara McNally; Finian Martin; John P Crown; Karin Jirström; Desmond G Higgins; William M Gallagher; Darran P O'Connor
Journal:  Clin Cancer Res       Date:  2012-10-11       Impact factor: 12.531

Review 5.  Deregulation and therapeutic potential of microRNAs in arthritic diseases.

Authors:  Rita Vicente; Danièle Noël; Yves-Marie Pers; Florence Apparailly; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

6.  MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3.

Authors:  Jun Zhao; Ting Lei; Congjie Xu; Huan Li; Wenmin Ma; Yunxia Yang; Shuming Fan; Yuchen Liu
Journal:  Biochem Biophys Res Commun       Date:  2013-07-31       Impact factor: 3.575

7.  Expression of the BCL6 gene in the pre- and postnatal mouse.

Authors:  S Bajalica-Lagercrantz; F Piehl; F Farnebo; C Larsson; J Lagercrantz
Journal:  Biochem Biophys Res Commun       Date:  1998-06-18       Impact factor: 3.575

8.  miR-339-3p inhibits proliferation and metastasis of colorectal cancer.

Authors:  Chang Zhou; Yenxia Lu; Xuenong Li
Journal:  Oncol Lett       Date:  2015-09-02       Impact factor: 2.967

9.  Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion.

Authors:  J M Locke; G da Silva Xavier; H R Dawe; G A Rutter; L W Harries
Journal:  Diabetologia       Date:  2013-10-23       Impact factor: 10.122

10.  Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells.

Authors:  Nan Jiang; Wei Chen; Jian-Wen Zhang; Yang Li; Xian-Cheng Zeng; Tong Zhang; Bin-Sheng Fu; Hui-Min Yi; Qi Zhang
Journal:  Mol Med Rep       Date:  2015-09-25       Impact factor: 2.952

View more
  8 in total

1.  BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).

Authors:  Yanhui Cai; Meagan A Watkins; Fengtian Xue; Yong Ai; Huiming Cheng; Cecily C Midkiff; Xiaolei Wang; Xavier Alvarez; Adi Narayana Reddy Poli; Joseph M Salvino; Ronald S Veazey; Luis J Montaner
Journal:  J Med Primatol       Date:  2019-10-01       Impact factor: 0.667

Review 2.  Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.

Authors:  Dharambir Kashyap; Hardeep Singh Tuli; Vivek Kumar Garg; Neelam Goel; Anupam Bishayee
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

3.  MicroRNA-187 exerts tumor-suppressing functions in osteosarcoma by targeting ZEB2.

Authors:  Dan Fei; Kunchi Zhao; Hongping Yuan; Jie Xing; Dongxu Zhao
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

4.  Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.

Authors:  Qian Wang; Wei Ding; Yihan Ding; Jingjing Ma; Zhaoye Qian; Jingxian Shao; Yufeng Li
Journal:  Oncotarget       Date:  2017-06-06

Review 5.  Non-Coding RNAs in Diffuse Large B-Cell Lymphoma.

Authors:  Yan Shi; Daihong Ding; Rongfeng Qu; Yan Tang; Shuhong Hao
Journal:  Onco Targets Ther       Date:  2020-11-24       Impact factor: 4.147

6.  BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.

Authors:  Yanhui Cai; Adi Narayana Reddy Poli; Surya Vadrevu; Kwasi Gyampoh; Colin Hart; Brian Ross; Matt Fair; Fengtian Xue; Joseph M Salvino; Luis J Montaner
Journal:  Eur J Immunol       Date:  2021-09-16       Impact factor: 5.532

7.  MicroRNA profiling in the dentate gyrus in epileptic rats: The role of miR-187-3p.

Authors:  Suya Zhang; Yubin Kou; Chunmei Hu; Yan Han
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

Review 8.  miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin's Lymphoma: Moving towards an RNA-Guided Precision Medicine.

Authors:  Mara Fernandes; Herlander Marques; Ana Luísa Teixeira; Rui Medeiros
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.